<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url><loc>https://mindmedicinelaw.com/briefing/compass-pathways-faces-fda-approval-and-dea-scheduling-hurdles-in-us-20261120-60779</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T15:03:53.181538+00:00</news:publication_date><news:title>Compass Pathways Faces FDA Approval and DEA Scheduling Hurdles in US</news:title><news:keywords>compass pathways, fda approval, dea scheduling, psilocybin therapy, controlled substances act, treatment-resistant depression, drug policy, clinical trials, rem, psychedelic medicine</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/us-house-panel-advances-psychedelic-mental-health-care-for-veterans-20261120-60686</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:05:02.126291+00:00</news:publication_date><news:title>US House Panel Advances Psychedelic Mental Health Care for Veterans</news:title><news:keywords>psychedelic policy, veterans mental health, us congress, bipartisan support, ptsd treatment, va clinical trials, federal research funding, mdma therapy, regulatory barriers, psychedelic access</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/addiction-professionals-assess-psychedelics-for-aud-prevention-in-us-20261119-60573</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:06:42.362366+00:00</news:publication_date><news:title>Addiction Professionals Assess Psychedelics for AUD Prevention in US</news:title><news:keywords>psychedelics, alcohol use disorder, prevention, addiction professionals, policy barriers, clinical trials, equity in access, public health, workforce training</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/meta-analysis-of-psilocybin-and-lsd-for-anxiety-rct-evidence-review-20261119-60610</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:06:30.541779+00:00</news:publication_date><news:title>Meta-Analysis of Psilocybin and LSD for Anxiety: RCT Evidence Review</news:title><news:keywords>psilocybin, LSD, anxiety disorders, systematic review, meta-analysis, dose-response, randomized controlled trials, psychedelic therapy, safety profile</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/mescaline-s-empathy-effects-5-ht2a-mechanism-in-human-study-20261119-60572</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:05:26.568417+00:00</news:publication_date><news:title>Mescaline’s Empathy Effects: 5-HT2A Mechanism in Human Study</news:title><news:keywords>mescaline, empathy, 5-HT2A receptor, oxytocin, psychedelic clinical trials, serotonergic psychedelics, psychiatric research, empathogenic effects, placebo-controlled study, policy implications</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/adverse-outcomes-after-psychedelic-therapy-u-s-clinical-and-policy-implications-20261119-60688</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:05:14.026509+00:00</news:publication_date><news:title>Adverse Outcomes After Psychedelic Therapy: U.S. Clinical and Policy Implications</news:title><news:keywords>psychedelic therapy, adverse outcomes, post-treatment support, informed consent, clinical trials, FDA guidance, integration protocols, risk communication, patient safety</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/psilocybin-study-highlights-reproducibility-challenges-in-clinical-research-20261119-60490</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T15:04:49.573758+00:00</news:publication_date><news:title>Psilocybin Study Highlights Reproducibility Challenges in Clinical Research</news:title><news:keywords>psilocybin reproducibility, clinical trial methodology, regulatory standards, psychedelic research, FDA approval process, publication bias, policy implications, CONSORT guidelines, long-term safety</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/monoamine-targeting-drugs-for-ptsd-efficacy-mechanisms-and-implications-20261118-60592</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T15:04:17.428400+00:00</news:publication_date><news:title>Monoamine-Targeting Drugs for PTSD: Efficacy, Mechanisms, and Implications</news:title><news:keywords>ptsd, monoamine targeting drugs, ssri, sertraline, paroxetine, off-label treatments, psychedelic therapeutics, mechanistic rationale, clinical trials, treatment gaps</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/prescribed-safer-supply-in-british-columbia-early-outcomes-and-policy-implicatio-20261118-60611</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T15:04:04.935422+00:00</news:publication_date><news:title>Prescribed Safer Supply in British Columbia: Early Outcomes and Policy Implications</news:title><news:keywords>prescribed safer supply, british columbia, harm reduction, depression, unregulated substance use, public health policy, cohort study, drug policy, service integration</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/eeg-fmri-fusion-methods-implications-for-psychedelic-neuroscience-20261118-60622</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:06:53.046334+00:00</news:publication_date><news:title>EEG-fMRI Fusion Methods: Implications for Psychedelic Neuroscience</news:title><news:keywords>eeg-fmri fusion, psychedelic neuroscience, multimodal neuroimaging, latent neural inference, clinical trial endpoints, biomarker development, interpretability challenges, validation standards, nonlinear modeling</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/lsd-and-first-episode-psychosis-neural-overlap-revealed-in-connectome-study-20261118-60577</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:06:07.015923+00:00</news:publication_date><news:title>LSD and First Episode Psychosis: Neural Overlap Revealed in Connectome Study</news:title><news:keywords>lsd, first episode psychosis, connectome, resting-state functional connectivity, dorsal attention network, sensorimotor network, psychotomimetic, psychedelic therapy, risk assessment, clinical trial design</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/hospital-management-of-ketamine-use-clinical-challenges-and-policy-implications-20261118-60626</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:05:56.123731+00:00</news:publication_date><news:title>Hospital Management of Ketamine Use: Clinical Challenges and Policy Implications</news:title><news:keywords>ketamine use disorder, hospital management, acute intoxication, withdrawal treatment, chronic complications, harm reduction, clinical protocols, policy implications, substance use screening</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/dissociation-in-esketamine-therapy-clinical-impact-and-practice-in-israel-20261118-60623</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:05:37.410458+00:00</news:publication_date><news:title>Dissociation in Esketamine Therapy: Clinical Impact and Practice in Israel</news:title><news:keywords>esketamine therapy, dissociation, treatment-resistant depression, trauma comorbidity, integration support, psychedelic-assisted therapy, clinical outcomes, israel mental health, antidepressant efficacy</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/psychedelic-intensity-predicts-ketamine-outcomes-new-evidence-20261118-60265</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T22:06:05.429339+00:00</news:publication_date><news:title>Psychedelic Intensity Predicts Ketamine Outcomes: New Evidence</news:title><news:keywords>ketamine therapy, psychedelic intensity, depression treatment, subjective experience, clinical outcomes, mindbloom psychedelic intensity scale, telehealth psychiatry, treatment response predictors, psychedelic clinical trials</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/pvn-as-central-hub-for-pain-emotion-comorbidity-implications-for-psychedelic-res-20261117-60318</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T22:07:19.564226+00:00</news:publication_date><news:title>PVN as Central Hub for Pain-Emotion Comorbidity: Implications for Psychedelic Research</news:title><news:keywords>hypothalamic paraventricular nucleus, pain-emotion comorbidity, crh oxytocin balance, neuropeptide systems, chronic pain, depression and anxiety, psychedelic trial design, neuromodulation, neuroinflammation, precision psychiatry</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/deep-learning-enhances-calcium-imaging-in-psychedelic-research-20261117-60301</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T22:07:05.227479+00:00</news:publication_date><news:title>Deep Learning Enhances Calcium Imaging in Psychedelic Research</news:title><news:keywords>deep learning, calcium imaging, neuronal dynamics, psychedelic research, preclinical studies, convolutional neural networks, data analysis, drug discovery, segmentation-agnostic, neuroscience methods</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/gabaergic-neuron-dysfunction-and-psychiatric-disorders-implications-for-psychede-20261117-60316</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T22:06:55.616602+00:00</news:publication_date><news:title>GABAergic Neuron Dysfunction and Psychiatric Disorders: Implications for Psychedelic Research</news:title><news:keywords>gabaergic neurons, psychiatric disorders, cell-type specificity, multi-omic analysis, clinical trial design, psychedelic mechanisms, biomarker discovery, e/i balance, precision psychiatry</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/psilocybin-s-effects-on-sleep-neurophysiology-in-mdd-aud-new-rct-insights-20261117-60303</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T22:06:45.730610+00:00</news:publication_date><news:title>Psilocybin’s Effects on Sleep Neurophysiology in MDD/AUD: New RCT Insights</news:title><news:keywords>psilocybin, sleep neurophysiology, randomized controlled trial, major depressive disorder, alcohol use disorder, sleep eeg, biomarkers, psychedelic therapy, clinical research</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/trkb-as-a-unifying-target-rethinking-serotoninergic-antidepressants-and-psychede-20261116-60579</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:06:18.879298+00:00</news:publication_date><news:title>TrkB as a Unifying Target: Rethinking Serotoninergic Antidepressants and Psychedelics</news:title><news:keywords>trkB, serotonin transporter, ssri mechanism, psychedelic antidepressants, bdnf signaling, clinical trial design, biomarkers, regulatory policy, neuroplasticity</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/helus-modified-psychedelic-achieves-phase-3-success-in-depression-20261116-60377</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T22:05:52.833112+00:00</news:publication_date><news:title>Helus' Modified Psychedelic Achieves Phase 3 Success in Depression</news:title><news:keywords>helus, modified psychedelic, phase 3 trial, depression treatment, clinical trial results, intellectual property, regulatory pathways, safety profile, next-generation psychedelics</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/mdma-assisted-psychotherapy-for-sexual-offending-prevention-trial-proposal-and-i-20261114-60288</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T22:06:34.548579+00:00</news:publication_date><news:title>MDMA-Assisted Psychotherapy for Sexual Offending Prevention: Trial Proposal and Implications</news:title><news:keywords>mdma-assisted psychotherapy, sexual offending prevention, paraphilic disorders, clinical trial ethics, public health policy, psychedelic research, regulatory safeguards, ptsd overlap, criminal justice innovation</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/cost-effectiveness-of-psychedelic-therapies-for-depression-and-ptsd-systematic-r-20261113-60291</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T22:07:30.026144+00:00</news:publication_date><news:title>Cost-Effectiveness of Psychedelic Therapies for Depression and PTSD: Systematic Review Insights</news:title><news:keywords>cost-effectiveness, psychedelic-assisted therapy, depression, ptsd, systematic review, health economics, insurance coverage, policy, clinical trials, mental health</news:keywords></news:news></url></urlset>